Brentuximab vedotin (BV), an anti-CD30 antibody–drug conjugate, has been approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of CD30-positive mycosis fungoides (MF). The gene discussed is TNFRSF8; the disease is mycosis fungoides.